Model Information:

Castrate-resistant prostate cancer (CRPC); Recurrent chromosomal abnormalities included losses on chromosomes10q (includingPTEN and MXI1), 12p, 13q (including Rb1), 17p (including TP53), 18q, 3Mb deletion between ERG and TMPRSS2 on Ch21, 6q, and 9q. Gains included the q-arm of X,which was confirmed by PCR for ARTMPRSS-ETS fusion.

Summary

Cancer Type Prostate Cancer
Subtype CRPC
Grade NA
Stage M(b1)
Ethnicity Western
Gender M
Age 67
Pathology Diagnosis

Castrate-resistant prostate cancer (CRPC); Recurrent chromosomal abnormalities included losses on chromosomes10q (includingPTEN and MXI1), 12p, 13q (including Rb1), 17p (including TP53), 18q, 3Mb deletion between ERG and TMPRSS2 on Ch21, 6q, and 9q. Gains included the q-arm of X,which was confirmed by PCR for ARTMPRSS-ETS fusion.

Biopsy Site primary
Treatment History HT, CT
Pathology QC Prostate cancer(PR6512-H149/5+C 10/1), poorly differentiated prostate adenocarcinoma; P504(+/-), 34bE12(nearly 1%: 1+), CK8(2+), PSA(<1%: 1+), Nkx3.1(2~3+), AR(3+), p63(2+)
Special Features CRPC, model expansion is needed prio to study.
Mouse Strain Rag2-/-?C-/-, NSG
TMA NA
Publication NA

Growth Characteristics

Additional Characteristics